25.9 USD
+0.19 (+0.74%)
25.9 USD
0 (0%)
AMPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMPH. These ratings would make AMPH suitable for value investing!
1. Profitability
1.1 Basic Checks
AMPH had positive earnings in the past year.
AMPH had a positive operating cash flow in the past year.
AMPH had positive earnings in each of the past 5 years.
Each year in the past 5 years AMPH had a positive operating cash flow.
1.2 Ratios
AMPH has a Return On Assets of 6.70%. This is amongst the best in the industry. AMPH outperforms 87.96% of its industry peers.
AMPH's Return On Equity of 14.37% is amongst the best of the industry. AMPH outperforms 88.48% of its industry peers.
The Return On Invested Capital of AMPH (8.51%) is better than 86.91% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMPH is in line with the industry average of 12.85%.
The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
AMPH has a better Profit Margin (15.43%) than 87.43% of its industry peers.
AMPH's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 20.73%, AMPH belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
AMPH's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 49.36%, AMPH is doing good in the industry, outperforming 64.40% of the companies in the same industry.
AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, AMPH has less shares outstanding
The number of shares outstanding for AMPH has been increased compared to 5 years ago.
Compared to 1 year ago, AMPH has an improved debt to assets ratio.
2.2 Solvency
AMPH has an Altman-Z score of 2.38. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of AMPH (2.38) is better than 62.30% of its industry peers.
AMPH has a debt to FCF ratio of 5.49. This is a neutral value as AMPH would need 5.49 years to pay back of all of its debts.
AMPH has a better Debt to FCF ratio (5.49) than 81.68% of its industry peers.
AMPH has a Debt/Equity ratio of 0.78. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
AMPH's Debt to Equity ratio of 0.78 is on the low side compared to the rest of the industry. AMPH is outperformed by 70.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.38 |
ROIC/WACC0.97
WACC8.76%
2.3 Liquidity
AMPH has a Current Ratio of 3.12. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
AMPH has a Current ratio of 3.12. This is comparable to the rest of the industry: AMPH outperforms 53.40% of its industry peers.
AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
AMPH has a Quick ratio (2.21) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased by -9.95% in the last year.
The Earnings Per Share has been growing by 61.62% on average over the past years. This is a very strong growth
The Revenue has decreased by -0.03% in the past year.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.82% yearly.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
AMPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.14% yearly.
The Revenue is expected to grow by 4.14% on average over the next years.
EPS Next Y-8.67%
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 7.53 indicates a rather cheap valuation of AMPH.
Compared to the rest of the industry, the Price/Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 93.72% of the companies listed in the same industry.
AMPH is valuated cheaply when we compare the Price/Earnings ratio to 26.76, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 6.89, the valuation of AMPH can be described as very cheap.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of AMPH to the average of the S&P500 Index (23.96), we can say AMPH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.53 | ||
| Fwd PE | 6.89 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
89.53% of the companies in the same industry are more expensive than AMPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.72 | ||
| EV/EBITDA | 7.18 |
4.3 Compensation for Growth
AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
5. Dividend
5.1 Amount
AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.9
+0.19 (+0.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners73.83%
Inst Owner Change0.4%
Ins Owners9.39%
Ins Owner Change3.23%
Market Cap1.19B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts80
Price Target32.64 (26.02%)
Short Float %10.32%
Short Ratio8.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-3.03%
PT rev (3m)-3.61%
EPS NQ rev (1m)5.33%
EPS NQ rev (3m)1.52%
EPS NY rev (1m)3.69%
EPS NY rev (3m)3.34%
Revenue NQ rev (1m)0.16%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)0.61%
Revenue NY rev (3m)0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.53 | ||
| Fwd PE | 6.89 | ||
| P/S | 1.65 | ||
| P/FCF | 10.72 | ||
| P/OCF | 7.82 | ||
| P/B | 1.53 | ||
| P/tB | 5.82 | ||
| EV/EBITDA | 7.18 |
EPS(TTM)3.44
EY13.28%
EPS(NY)3.76
Fwd EY14.52%
FCF(TTM)2.42
FCFY9.33%
OCF(TTM)3.31
OCFY12.8%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.12
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.38 |
F-Score5
WACC8.76%
ROIC/WACC0.97
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.67%
EPS Next 2Y-1.31%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.38%
EBIT Next 3Y0.74%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -8.67% in the next year.